NCT07844785Not yet recruiting
Metabolic and Hormonal Parameters in Women With Polyendocrine Metabolic Ovarian Syndrome
Correlation of Serum and Salivary Fetuin-A and Resistin Levels With Metabolic and Hormonal Parameters in Women With Polyendocrine Metabolic Ovarian Syndrome
Source: ClinicalTrials.gov · Last updated 28 Sept 2026
Brief summary (registry, in English)
Polyendocrine Metabolic Ovarian Syndrome (PMOS) is a common endocrine and metabolic disorder associated with insulin resistance, hyperandrogenism, and an increased risk of long-term metabolic complications. Fetuin-A and resistin are adipokines implicated in insulin resistance and chronic inflammation and may serve as potential biomarkers for metabolic dysfunction in women with PMOS. This prospective observational case-control study aims to compare serum and salivary Fetuin-A and resistin levels between women with PMOS and healthy controls. The study will evaluate the correlation between serum and salivary biomarker concentrations and investigate their associations with insulin resistance, lipid profile, and hormonal parameters. The findings may help determine whether salivary measurements can serve as reliable non-invasive biomarkers for the diagnosis and metabolic assessment of PMOS.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 80 (estimated)
- First submitted
- 10 Aug 2026
- Start date
- 1 Sept 2026
- Primary completion date
- 1 Feb 2027
- Lead sponsor
- Istinye University
- NCT number
- NCT07844785
What you commit to
- Study type: Observational
- Planned participants: 80
- From 1 Sept 2026 to the primary completion date, 1 Feb 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of hormonal contraceptives, anti-androgens, glucocorticoids, metformin, or insulin-sensitizing medications within the previous 3 months
Other illness
- Diabetes mellitus
- Chronic kidney or liver disease
- Cushing syndrome
- Severe periodontal disease or active oral infection
Other
- Pregnancy or breastfeeding
- Thyroid dysfunction
- Hyperprolactinemia
- Non-classic congenital adrenal hyperplasia
Who the study is looking for
- PMOS Group:
- Female, aged 18-35 years
- Diagnosis of Polyendocrine Metabolic Ovarian Syndrome (PMOS) according to the Rotterdam criteria
- BMI \<30 kg/m²
- Written informed consent
- Healthy Control Group:
- Female, aged 18-35 years
- Regular menstrual cycles
- No diagnosis of PMOS
- BMI \<30 kg/m²
- Written informed consent
Age in the registry: 18 years to 35 years · Sex: Female · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.